apixaban teva 2.5 mg film-coated tablets
norton waterford - apixaban - film-coated tablet - apixaban
apixaban teva 5 mg film-coated tablets
norton waterford - apixaban - film-coated tablet - apixaban
sudocrem antiseptic healing cream
norton waterford - benzyl alcohol; benzyl cinnamate; benzyl benzoate; wool fat; zinc oxide - cream - zinc products
duoresp® spiromax® dry powder for inhalation 160 mcg4.5 mcg
teva pharmaceutical investments singapore pte. ltd. - budesonide (micronised); formoterol fumarate dihydrate (micronised) - powder, metered - budesonide (micronised) 160 mcg / inhalation; formoterol fumarate dihydrate (micronised) 4.5 mcg / inhalation
duoresp® spiromax® dry powder for inhalation 320 mcg9 mcg
teva pharmaceutical investments singapore pte. ltd. - budesonide (micronised); formoterol fumarate dihydrate (micronised) - powder, metered - budesonide (micronised) 320 mcg / inhalation; formoterol fumarate dihydrate (micronised) 9 mcg / inhalation
flucloxacillin 250 milligram capsule
norton healthcare limited t/a ivax pharmaceuticals uk - flucloxacillin sodium - capsule - 250 milligram - beta-lactamase resistant penicillins
flucloxacillin 500 milligram capsule
norton healthcare limited t/a ivax pharmaceuticals uk - flucloxacillin sodium - capsule - 500 milligram - beta-lactamase resistant penicillins
paxene
norton healthcare ltd. - paclitaxel - sarcoma, kaposi; carcinoma, non-small-cell lung; ovarian neoplasms; breast neoplasms - antineoplastic agents - paxene is indicated for the treatment of patients with:• advanced aids-related kaposi's sarcoma (aids-ks) who have failed prior liposomal anthracycline therapy;• metastatic carcinoma of the breast (mbc) who have failed, or are not candidates for standard anthracycline-containing therapy;• advanced carcinoma of the ovary (aoc) or with residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment;• metastatic carcinoma of the ovary (moc) after failure of platinum-containing combination therapy without taxanes as second-line treatment;• non-small cell lung carcinoma (nsclc) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin. limited efficacy data supports this indication (see section 5.1).
phosphonortonic 20 % injectable solution
vetoquinol ireland limited - toldimfos sodium trihydrate - solution for injection - 20 %w/v - toldimfos - bovine, equine - food - vitamins & minerals
phosphonortonic 20% injectable solution
vetoquinol ireland limited - toldimfos sodium trihydrate - solution for injection - 20 percent weight/volume - toldimfos - cattle, horses - vitamins and minerals